SB-236057 is a compound which is a potent and
selectiveinverse agonist for the
serotoninreceptor5-HT1B, acting especially at 5-HT1B autoreceptors on nerve terminals. It produces a rapid increase in
serotonin levels in the brain, and was originally researched as a potential
antidepressant.[1][2] However subsequent research found that SB-236,057 also acts as a potent
teratogen, producing severe musculoskeletal birth defects when rodents were exposed to it during pregnancy. This has made it of little use for research into its original applications, yet has made it useful for studying embryonic development instead.[3][4]
References
^Middlemiss DN, Göthert M, Schlicker E, Scott CM, Selkirk JV, Watson J, et al. (June 1999). "SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor". European Journal of Pharmacology. 375 (1–3): 359–65.
doi:
10.1016/s0014-2999(99)00262-9.
PMID10443589.
^Augustine-Rauch KA, Zhang QJ, Posobiec L, Mirabile R, DeBoer LS, Solomon HM, Wier PJ (October 2004). "SB-236057: Critical window of sensitivity study and embryopathy of a potent musculoskeletal teratogen". Birth Defects Research. Part A, Clinical and Molecular Teratology. 70 (10): 773–88.
doi:
10.1002/bdra.20079.
PMID15472921.
^Augustine-Rauch KA, Zhang QJ, Leonard JL, Chadderton A, Welsh MJ, Rami HK, et al. (October 2004). "Evidence for a molecular mechanism of teratogenicity of SB-236057, a 5-HT1B receptor inverse agonist that alters axial formation". Birth Defects Research. Part A, Clinical and Molecular Teratology. 70 (10): 789–807.
doi:
10.1002/bdra.20076.
PMID15472891.
SB-236057 is a compound which is a potent and
selectiveinverse agonist for the
serotoninreceptor5-HT1B, acting especially at 5-HT1B autoreceptors on nerve terminals. It produces a rapid increase in
serotonin levels in the brain, and was originally researched as a potential
antidepressant.[1][2] However subsequent research found that SB-236,057 also acts as a potent
teratogen, producing severe musculoskeletal birth defects when rodents were exposed to it during pregnancy. This has made it of little use for research into its original applications, yet has made it useful for studying embryonic development instead.[3][4]
References
^Middlemiss DN, Göthert M, Schlicker E, Scott CM, Selkirk JV, Watson J, et al. (June 1999). "SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor". European Journal of Pharmacology. 375 (1–3): 359–65.
doi:
10.1016/s0014-2999(99)00262-9.
PMID10443589.
^Augustine-Rauch KA, Zhang QJ, Posobiec L, Mirabile R, DeBoer LS, Solomon HM, Wier PJ (October 2004). "SB-236057: Critical window of sensitivity study and embryopathy of a potent musculoskeletal teratogen". Birth Defects Research. Part A, Clinical and Molecular Teratology. 70 (10): 773–88.
doi:
10.1002/bdra.20079.
PMID15472921.
^Augustine-Rauch KA, Zhang QJ, Leonard JL, Chadderton A, Welsh MJ, Rami HK, et al. (October 2004). "Evidence for a molecular mechanism of teratogenicity of SB-236057, a 5-HT1B receptor inverse agonist that alters axial formation". Birth Defects Research. Part A, Clinical and Molecular Teratology. 70 (10): 789–807.
doi:
10.1002/bdra.20076.
PMID15472891.